Teva Pharmaceutical Industries Ltd (TEVA) Lowered to "Hold" at BidaskClub

Chelsea West
August 5, 2017

(TEVA - Free Report) is a global pharmaceutical company with a strong presence in the generics as well as branded markets. Chevy Chase Trust Holdings Inc. raised its position in Teva Pharmaceutical Industries Limited by 7.5% in the second quarter. The Focused Wealth Management Inc holds 29,345 shares with $1.06M value, up from 17,900 last quarter. The latest exchange of 9.17 Million shares is above its average trading activity of 7.79 Million shares. However, McClellan warned, the company may "face a risk in breaching these covenants" should the dollar continue to depreciate against the euro and the Japanese yen, and Teva fails to raise enough proceeds from the sale of assets. Inc. now owns 69,183 shares of the company's stock worth $2,220,000 after buying an additional 295 shares during the last quarter. "We would be more positive on Teva shares if generic drug pricing improves and/or the brand drug launches and pipeline advancements exceed expectations". Institutional investors own 56.20% of the company's stock.

Teva Pharmaceutical Industries Limited (TEVA) price traded at a gap of -25.02% from an average price of last twenty days and stands at a distance of -22.81% away from it's an average price of recent fifty days. Bank Hapoalim BM now owns 11,673 shares of the company's stock valued at $375,000 after buying an additional 980 shares during the period. Teva Pharmaceutical Industries Limited has a 12 month low of $20.41 and a 12 month high of $55.79. It has a 36-month beta of 0.46, so you might not be in for a bumpy ride. The firm has a 50-day moving average of $32.05 and a 200 day moving average of $32.28.

A number of research firms have recently weighed in on TEVA. Stock investors acquired 66,716 put options on the company. This is an increase of approximately 864% compared to the typical daily volume of 6,922 put options. Tt International sold 748,351 shares as Teva Pharmaceutical Inds Ltd (TEVA)'s stock declined 15.11%.

The company reported an 18.4 percent drop in second-quarter earnings on Thursday, with earnings per share falling from $1.25 in the second quarter of 2016 to $1.02 in the second quarter of 2017. The company had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same period in the prior year, the company posted $1.20 earnings per share. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries Limited from a "sell" rating to a "hold" rating in a research report on Monday, April 17th.

More news: Teen Jumps Out Of Plane's Emergency Exit Onto SFO Tarmac

WARNING: This story was first posted by StockNewsTimes and is the property of of StockNewsTimes.

COPYRIGHT VIOLATION NOTICE: This article was reported by Stock Observer and is owned by of Stock Observer. The correct version of this report can be viewed at

TEVA has been the subject of several research reports. Equity analyst BTIG Research both downgraded the stock and lowered the price target on November 16 changing the price objective from $75.00 to $42.00 and altering the rating from "Buy" to "Equal-Weight".

Shares of healthcare player Teva Pharmaceutical Industries (TEVA) are plunging again on Friday, after a monster gap-down on Thursday with heavy volume. Oppenheimer Holdings, Inc. set a $43.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the stock a "buy" rating in a research report on Thursday, April 6th. For the past 5 years, the company's revenue has grown 3.6%, while the company's earnings per share has grown -53%. Nineteen equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company.

Other reports by TheSundaySentinel

Discuss This Article